[Form 4] Vita Coco Company, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Martin Roper, CEO and Director of Vita Coco Company, Inc. (COCO), reported open-market sales of common stock executed under a Rule 10b5-1 trading plan on September 22 and 23, 2025. The filing shows two sales by the reporting person of 5,000 shares on 09/22/2025 and 5,000 shares on 09/23/2025 at weighted-average prices in the ~$40.14–$40.52 range, leaving 324,297 shares held directly after the 09/23 sale. The form also discloses multiple indirect holdings through family trusts and a spouse, and a total of 1,099,460 outstanding stock options across several grant dates and exercise prices, including fully vested options exercisable now.

Positive

• Sales were executed under a Rule 10b5-1 trading plan, indicating pre-arranged transactions
• Some stock options are fully vested and currently exercisable, which provides clarity on management's compensation status

Negative

• Reporting person sold a total of 10,000 shares (5,000 on 09/22/2025 and 5,000 on 09/23/2025), reducing direct holdings to 324,297 shares
• There are 1,099,460 outstanding stock options across multiple grants, including large fully vested tranches

Insights

Financial Analyst

TL;DR: CEO sold 10,000 shares via a pre-arranged 10b5-1 plan; large outstanding option pool noted (1,099,460 options).

The transactions are disclosed as Rule 10b5-1-plan sales, indicating pre-specified disposition rather than opportunistic trading. The direct holdings declined to 324,297 shares after the reported sales. From an equity-structure perspective, the filing explicitly lists 1,099,460 stock options across multiple grant vintages and exercise prices, including sizeable fully vested tranches, which are relevant when modeling potential dilution and future share count if exercised.

Corporate Governance Expert

TL;DR: Insider sales were executed under an established trading plan; multiple family trust holdings and exercisable options are disclosed.

The filing clearly states the sales were effected pursuant to a Rule 10b5-1 trading plan, which is standard practice for planned insider disposals. It also identifies indirect holdings through the Christopher G. Roper, Peter S. Roper, and Thomas L. Roper Exempt Family Trusts and a spouse position. Several option grants are noted as fully vested and exercisable, a governance detail investors monitor for executive alignment and compensation realization.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Roper Martin

(Last) (First) (Middle)

250 PARK AVE SOUTH

SEVENTH FLOOR

(Street)

NEW YORK NY 10003

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vita Coco Company, Inc. [ COCO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/22/2025		S(1)		5,000	D	$40.168(2)	329,297	D
Common Stock	09/23/2025		S(1)		5,000	D	$40.515(3)	324,297	D
Common Stock	09/22/2025		S(1)		5,000	D	$40.142(4)	263,806	I	by Chris Roper FT(5)
Common Stock	09/23/2025		S(1)		5,000	D	$40.515(6)	258,806	I	by Chris Roper FT(5)
Common Stock	09/22/2025		S(1)		5,000	D	$40.125(7)	262,915	I	by Peter Roper FT(8)
Common Stock	09/23/2025		S(1)		5,000	D	$40.517(9)	257,915	I	by Peter Roper FT(8)
Common Stock	09/22/2025		S(1)		5,000	D	$40.147(10)	263,931	I	by Thomas Roper FT(11)
Common Stock	09/23/2025		S(1)		5,000	D	$40.515(12)	258,931	I	by Thomas Roper FT(11)
Common Stock								61,200	I	by Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$10.178							(13)	09/19/2029	Common Stock	579,670		579,670	D
Non-Qualified Stock Option (right to buy)	$10.178							(14)	01/11/2031	Common Stock	40,950		40,950	D
Non-Qualified Stock Option (right to buy)	$15							(15)	10/21/2031	Common Stock	298,507		298,507	D
Non-Qualified Stock Option (right to buy)	$16.91							(16)	03/10/2033	Common Stock	46,875		46,875	D
Non-Qualified Stock Option (right to buy)	$26.18							(17)	03/04/2034	Common Stock	62,743		62,743	D
Non-Qualified Stock Option (right to buy)	$32.78							(18)	03/03/2035	Common Stock	70,715		70,715	D

Explanation of Responses:

1. The sales of shares of common stock reported were effected pursuant to a Rule 10b5-1 trading plan.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.40, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.24 to $40.92, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.37, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

5. These shares are held by the Christopher G. Roper Exempt Family Trust.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.24 to $40.92, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.38, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

8. These shares are held by the Peter S. Roper Exempt Family Trust.

9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.51 to $40.92, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.41, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

11. These shares are held by the Thomas L. Roper Exempt Family Trust.

12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.56 to $40.92, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

13. The stock option is fully vested and currently exercisable.

14. The stock option is fully vested and currently exercisable.

15. The stock option vests in four equal annual installments beginning on November 27, 2022.

16. The stock option vests in four equal annual installments beginning on March 10, 2024.

17. The stock option vests in four equal annual installments beginning on March 4, 2025.

18. The Stock Option vests in four equal annual installments beginning in March 3, 2026.

	By: Alison Klein, Attorney-in-Fact For: Martin Roper	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Martin Roper (COCO) report on Form 4?

The Form 4 reports sales of 5,000 shares on 09/22/2025 and 5,000 shares on 09/23/2025, executed under a Rule 10b5-1 trading plan.

What were the prices for the shares sold by the reporting person?

The filing lists weighted-average prices in ranges: ~$40.00–$40.40 on 09/22/2025 and ~$40.24–$40.92 on 09/23/2025, with specific weighted averages reported per line.

How many shares does Martin Roper directly own after these transactions?

After the reported sales, the filing shows Martin Roper directly beneficially owned 324,297 shares following the 09/23/2025 sale.

What derivative securities did the Form 4 disclose?

Table II discloses multiple non-qualified stock options totaling 1,099,460 options across various exercise prices and vesting schedules, with several grants fully vested and currently exercisable.

Were any sales noted as pre-arranged plans?

Yes. The filing explicitly states the sales were effected pursuant to a Rule 10b5-1 trading plan.